AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
NORTH CHICAGO, Ill., Dec. 19, 2016 -- (Healthcare Sales &Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the company'... Biopharmaceuticals, FDA AbbVie, Glecaprevir, Pibrentasvir, Hepatitis C virus
Publication date: Available online 3 July 2020Source: Journal of Clinical and Experimental HepatologyAuthor(s): Gulzar Ahmad Dar, Ghulam Nabi Yattoo, G.M. Gulzar, Jaswinder Singh Sodhi, Suresh Gorka, Mushtaq Ahmad Laway
Authors: Khan MU, Mahmoud MI, Butt AA Abstract INTRODUCTION: Hepatitis C virus (HCV) infection is associated with an increased incidence and progression of chronic kidney disease (CKD), as well as higher mortality in CKD and renal transplant patients. Direct acting antiviral agents (DAAs) have revolutionized the treatment of HCV, with viral eradication attained in 90-100% of treated patients. DAAs have an excellent safety and tolerability profile in CKD and renal transplant patients. AREAS COVERED: In this review, we discuss the association of HCV with incidence and progression of CKD as well as its effect on o...
Conclusion: To our knowledge, only 6 cases of cranial CCC have been reported, and only 2 reported mixed cranial/spinal involvement. We report a rare case of CCC metastasis to the spine and cranium that was treated with surgery, chemotherapy, and radiotherapy. CCC should be considered an exceedingly rare etiology with treatment options aimed solely at palliation. This case supplements the existing literature to inform medical and surgical decision-making. PMID: 32612476 [PubMed]
Authors: Herrero JI, Ampuero J, Fernández Rodríguez CM Abstract Hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma, as well as the primary indication for liver transplant in Europe. The highly effective direct-acting antivirals currently available make it possible to achieve the hepatitis C elimination targets set by the World Health Organization. For this, population screening and one-step diagnosis are fundamental strategies. PMID: 32611193 [PubMed - as supplied by publisher]
Authors: Monoe C, Shimizu H, Kitaguchi K, Funakoshi H Abstract Amiodarone, prescribed for cardiac conditions, including dysrhythmia, is associated with bradycardia. However, few reports have demonstrated that bradycardia is observed when amiodarone is used in combination with sofosbuvir, a direct-acting antiviral drug for chronic hepatitis C. We herein report the case of a male patient in his 70s with chronic atrial fibrillation and prostatic hyperplasia and was also taking amiodarone, who experienced severe bradycardia and syncope a day after taking sofosbuvir and ribavirin for chronic hepatitis C. After discontin...
Analyst, 2020, Accepted Manuscript DOI: 10.1039/D0AN01111H, PaperFatih Ozefe, Ahu Arslan Yildiz This work describes development of smartphone-assisted magnetic levitation assay for Point-of-Care (PoC) applications. Magnetic levitation is a technique that detects and separates particles based on their density differences in a... The content of this RSS Feed (c) The Royal Society of Chemistry
Conclusions: The results of our study suggest that low-dose IL-2 has therapeutic effects on DSS-induced colitis and potential clinical value in treating UC.
Conclusion: Post-transplantation treatment of chronic HCV is preferred in KTRs. The sofosbuvir/daclatasvir regimen as an interferon-free therapy is a safe, effective option for HCV infection in pediatric KTRs, who can tolerate sofosbuvir/daclatasvir well and respond favorably without significant adverse events. PMID: 32606888 [PubMed]
Direct-acting antivirals (DAAs) cure most cases of chronic hepatitis C virus (HCV) infections. However, a small percentage of patients relapse with reappearance of viremia after a full course of therapy. Although most who relapse require retreatment, some patients spontaneously clear HCV without additional therapy. We studied patients who relapsed with detectable HCV RNA after a full course of DAA therapy and then spontaneously cleared the HCV infection without retreatment.
Value Health. 2020;23(1):127 –137.